• Je něco špatně v tomto záznamu ?

Anti-SARS-CoV-2 Vaccination and Antibody Response in Patients With Inflammatory Bowel Disease on Immune-modifying Therapy: Prospective Single-Tertiary Study

K. Cerna, D. Duricova, M. Lukas, N. Machkova, V. Hruba, K. Mitrova, K. Kubickova, M. Kostrejova, V. Teplan, M. Vasatko, K. Kastylova, M. Lukas

. 2022 ; 28 (10) : 1506-1512. [pub] 2022Oct03

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc22033133

BACKGROUND: Patients with inflammatory bowel disease (IBD) on immune-modifying treatment could be at an increased risk for severe coronavirus disease 2019 (COVID-19); thus, data on the efficacy and safety of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) vaccines are essential. We conducted a prospective study of IBD patients vaccinated with BNT162b2, CX-024414, and ChAdOx1 nCoV-19 vaccines. The aim was to evaluate the rate and magnitude of seroconversion, assess the effect of different immune-modifying treatment modalities on the magnitude of anti-SARS-CoV-2 IgG antibody levels, and analyze the impact of anti-SARS-CoV-2 vaccination on the inflammatory biomarkers of IBD. METHODS: The study included 602 IBD patients and 168 immunocompetent health care workers serving as controls. Serum anti-SARS-CoV-2 IgG antibodies were measured by chemiluminescent microparticle immunoassay before the vaccination and 8 weeks after the vaccination. RESULTS: Of IBD patients, 82.2% were receiving biological treatment: most of them were treated with antitumor necrosis factor (TNF)-α inhibitors (48.5%), and just under half of them were treated with concomitant thiopurines or methotrexate, followed by vedolizumab (18.6%) and ustekinumab (15.1%). Only 8.1% of patients were on 5-aminosalicylates, and a minority (2.2%) were treatment-free. The postvaccine seropositivity rate among IBD patients and controls was 97.8% vs 100%. Median anti-SARS-CoV-2 IgG levels were lower among IBD recipients of ChAdOx1 nCoV-19 compared with 2 other vaccines (P < .0001) and control ChAdOx1 nCoV-19 recipients (P = .01). No correlation was found between serum trough levels and anti-SARS-CoV-2 IgG concentrations for any of the biological drugs used. The TNF-α inhibitors with concomitant immunosuppressive treatment but no other treatment modalities were associated with a lower postvaccination antibody response (P < .0001). When evaluating the laboratory activity of IBD by C-reactive protein and fecal calprotectin levels, no significant differences were found before the vaccination and 8 weeks after its completion. CONCLUSIONS: Our findings warrant particular attention to the anti-SARS-CoV-2 vaccination of IBD patients treated with TNF-α inhibitors with concomitant immunomodulators and show the priority of mRNA vaccines in this specific group of patients.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22033133
003      
CZ-PrNML
005      
20230131151202.0
007      
ta
008      
230120s2022 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1093/ibd/izab301 $2 doi
035    __
$a (PubMed)34849919
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Cerna, Karin $u Clinical and Research Centre for Inflammatory Bowel Disease ISCARE and First Faculty of Medicine, Charles University, Prague, Czech Republic $u GENNET Prague, Czech Republic $1 https://orcid.org/0000000315935899
245    10
$a Anti-SARS-CoV-2 Vaccination and Antibody Response in Patients With Inflammatory Bowel Disease on Immune-modifying Therapy: Prospective Single-Tertiary Study / $c K. Cerna, D. Duricova, M. Lukas, N. Machkova, V. Hruba, K. Mitrova, K. Kubickova, M. Kostrejova, V. Teplan, M. Vasatko, K. Kastylova, M. Lukas
520    9_
$a BACKGROUND: Patients with inflammatory bowel disease (IBD) on immune-modifying treatment could be at an increased risk for severe coronavirus disease 2019 (COVID-19); thus, data on the efficacy and safety of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) vaccines are essential. We conducted a prospective study of IBD patients vaccinated with BNT162b2, CX-024414, and ChAdOx1 nCoV-19 vaccines. The aim was to evaluate the rate and magnitude of seroconversion, assess the effect of different immune-modifying treatment modalities on the magnitude of anti-SARS-CoV-2 IgG antibody levels, and analyze the impact of anti-SARS-CoV-2 vaccination on the inflammatory biomarkers of IBD. METHODS: The study included 602 IBD patients and 168 immunocompetent health care workers serving as controls. Serum anti-SARS-CoV-2 IgG antibodies were measured by chemiluminescent microparticle immunoassay before the vaccination and 8 weeks after the vaccination. RESULTS: Of IBD patients, 82.2% were receiving biological treatment: most of them were treated with antitumor necrosis factor (TNF)-α inhibitors (48.5%), and just under half of them were treated with concomitant thiopurines or methotrexate, followed by vedolizumab (18.6%) and ustekinumab (15.1%). Only 8.1% of patients were on 5-aminosalicylates, and a minority (2.2%) were treatment-free. The postvaccine seropositivity rate among IBD patients and controls was 97.8% vs 100%. Median anti-SARS-CoV-2 IgG levels were lower among IBD recipients of ChAdOx1 nCoV-19 compared with 2 other vaccines (P < .0001) and control ChAdOx1 nCoV-19 recipients (P = .01). No correlation was found between serum trough levels and anti-SARS-CoV-2 IgG concentrations for any of the biological drugs used. The TNF-α inhibitors with concomitant immunosuppressive treatment but no other treatment modalities were associated with a lower postvaccination antibody response (P < .0001). When evaluating the laboratory activity of IBD by C-reactive protein and fecal calprotectin levels, no significant differences were found before the vaccination and 8 weeks after its completion. CONCLUSIONS: Our findings warrant particular attention to the anti-SARS-CoV-2 vaccination of IBD patients treated with TNF-α inhibitors with concomitant immunomodulators and show the priority of mRNA vaccines in this specific group of patients.
650    _2
$a protilátky virové $7 D000914
650    _2
$a tvorba protilátek $7 D000917
650    _2
$a vakcína BNT162 $7 D000090982
650    _2
$a C-reaktivní protein $x metabolismus $7 D002097
650    12
$a COVID-19 $x prevence a kontrola $7 D000086382
650    _2
$a ChAdOx1 nCoV-19 $7 D000090985
650    _2
$a lidé $7 D006801
650    _2
$a imunoglobulin G $7 D007074
650    12
$a idiopatické střevní záněty $x farmakoterapie $7 D015212
650    _2
$a leukocytární L1-antigenní komplex $7 D039841
650    _2
$a methotrexát $7 D008727
650    _2
$a prospektivní studie $7 D011446
650    _2
$a SARS-CoV-2 $7 D000086402
650    _2
$a TNF-alfa $x metabolismus $7 D014409
650    _2
$a ustekinumab $7 D000069549
650    _2
$a vakcinace $7 D014611
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Duricova, Dana $u Clinical and Research Centre for Inflammatory Bowel Disease ISCARE and First Faculty of Medicine, Charles University, Prague, Czech Republic $u Institute of Pharmacology, First Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Lukas, Martin $u Clinical and Research Centre for Inflammatory Bowel Disease ISCARE and First Faculty of Medicine, Charles University, Prague, Czech Republic $u Institute of Animal Physiology and Genetics, Czech Academy of Sciences, Libechov, Czech Republic
700    1_
$a Machkova, Nadezda $u Clinical and Research Centre for Inflammatory Bowel Disease ISCARE and First Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Hruba, Veronika $u Clinical and Research Centre for Inflammatory Bowel Disease ISCARE and First Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Mitrova, Katarina $u Clinical and Research Centre for Inflammatory Bowel Disease ISCARE and First Faculty of Medicine, Charles University, Prague, Czech Republic $u Department of Pediatrics, University Hospital Motol and Second Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Kubickova, Kristyna $u Clinical and Research Centre for Inflammatory Bowel Disease ISCARE and First Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Kostrejova, Marta $u Clinical and Research Centre for Inflammatory Bowel Disease ISCARE and First Faculty of Medicine, Charles University, Prague, Czech Republic $u Department of Internal Medicine, Hospital of the Sisters of Mercy of St. Charles Borromeo, Prague, Czech Republic
700    1_
$a Teplan, Vladimir $u Clinical and Research Centre for Inflammatory Bowel Disease ISCARE and First Faculty of Medicine, Charles University, Prague, Czech Republic $u Institute for Postgradual Medical Education, Prague, Czech Republic $u Department of Internal Medicine, University Hospital and Medical Faculty, Ostrava, Czech Republic
700    1_
$a Vasatko, Martin $u Clinical and Research Centre for Inflammatory Bowel Disease ISCARE and First Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Kastylova, Kristyna $u Clinical and Research Centre for Inflammatory Bowel Disease ISCARE and First Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Lukas, Milan $u Clinical and Research Centre for Inflammatory Bowel Disease ISCARE and First Faculty of Medicine, Charles University, Prague, Czech Republic
773    0_
$w MED00002243 $t Inflammatory bowel diseases $x 1536-4844 $g Roč. 28, č. 10 (2022), s. 1506-1512
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34849919 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230120 $b ABA008
991    __
$a 20230131151158 $b ABA008
999    __
$a ok $b bmc $g 1891726 $s 1184468
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2022 $b 28 $c 10 $d 1506-1512 $e 2022Oct03 $i 1536-4844 $m Inflammatory bowel diseases $n Inflamm Bowel Dis $x MED00002243
LZP    __
$a Pubmed-20230120

Najít záznam

Citační ukazatele

Možnosti archivace